James A. de Lemos
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
James A. de Lemos has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Robert Patrick Giugliano
TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA
3 shared publications Carolyn H. McCabe
2 shared publicationsElliott M. Antman
2 shared publicationsEugene Braunwald
2 shared publicationsAndrew Charlesworth
1 shared publicationC. Michael Gibson
From the Cardiovascular Division, Brigham and Women’s Hospital (J.A.d., E.M.A., C.H.M., R.P.G., S.A.C., E.B.), Boston Mass; University of California at San Francisco Medical Center (C.M.G., S.A.M.), San Francisco; Centocor (K.A.), Malvern, Pa; Eli Lilly Inc (J.S.), Indianapolis, Ind; Heart Center (M.J.F.), Sarasota, Fla; Afdeling Cardiologie (R.V.), Amsterdam, the Netherlands; and Universitair Zikenhuis Gasthuisberg (F.V.), Leuven, Belgium
1 shared publication
Latest Publications
- 1 September 2000
- Published by Elsevier in American Heart Journal
- Vol. 140 (3) , 373-378
Very early risk stratification after thrombolytic therapy with a bedside myoglobin assay and the 12-lead electrocardiogram
- 1 September 2000
- Published by Elsevier in American Heart Journal
- Vol. 140 (3) , 373-378
Very early risk stratification after thrombolytic therapy with a bedside myoglobin assay and the 12-lead electrocardiogram
- 1 August 2000
- Published by Elsevier in Clinica Chimica Acta
- Vol. 298 (1-2) , 85-97
Heart-Type Fatty Acid Binding Protein as a marker of reperfusion after thrombolytic therapy
- 1 August 2000
- Published by Elsevier in Clinica Chimica Acta
- Vol. 298 (1-2) , 85-97
Heart-Type Fatty Acid Binding Protein as a marker of reperfusion after thrombolytic therapy
Plasma concentration of soluble vascular cell adhesion molecule-1 and subsequent cardiovascular risk
- 25 January 2000
- Published by Wolters Kluwer Health in Circulation
- Vol. 101 (3) , 239-243
Abciximab Improves Both Epicardial Flow and Myocardial Reperfusion in ST-Elevation Myocardial Infarction
Background —In the presence of ST-elevation myocardial infarction, patients with successful epicardial reperfusion (TIMI 3 flow) but persistent ST elevation on a 12-lead ECG are at high risk for subsequent death and left ventricular dysfunction. In the TIMI 14 trial, a dose-ranging angiographic study, combined therapy with abciximab plus reduced-dose tPA enhanced the speed and efficacy of epicardial reperfusion. We determined whether the combination of abciximab plus reduced-dose tPA provided additional benefit in terms of myocardial reperfusion, as evidenced by greater resolution of ST elevation. Methods and Results —All 346 patients with interpretable baseline and 90-minute ECGs, treated with either tPA alone or abciximab plus reduced-dose tPA (combination therapy), were included. Patients receiving combination therapy (n=221) had a 59% rate of complete (≥70%) ST resolution at 90 minutes versus 37% in those treated with tPA alone (n=125) ( P P =0.0002). Conclusions —Combination therapy with abciximab and reduced-dose tPA improves myocardial (microvascular) reperfusion, as reflected in greater ST-segment resolution, in addition to epicardial flow. This finding may translate into improved clinical outcomes by enhancing myocardial salvage.
- 25 January 2000
- Published by Wolters Kluwer Health in Circulation
- Vol. 101 (3) , 239-243
Abciximab Improves Both Epicardial Flow and Myocardial Reperfusion in ST-Elevation Myocardial Infarction
Background —In the presence of ST-elevation myocardial infarction, patients with successful epicardial reperfusion (TIMI 3 flow) but persistent ST elevation on a 12-lead ECG are at high risk for subsequent death and left ventricular dysfunction. In the TIMI 14 trial, a dose-ranging angiographic study, combined therapy with abciximab plus reduced-dose tPA enhanced the speed and efficacy of epicardial reperfusion. We determined whether the combination of abciximab plus reduced-dose tPA provided additional benefit in terms of myocardial reperfusion, as evidenced by greater resolution of ST elevation. Methods and Results —All 346 patients with interpretable baseline and 90-minute ECGs, treated with either tPA alone or abciximab plus reduced-dose tPA (combination therapy), were included. Patients receiving combination therapy (n=221) had a 59% rate of complete (≥70%) ST resolution at 90 minutes versus 37% in those treated with tPA alone (n=125) ( P P =0.0002). Conclusions —Combination therapy with abciximab and reduced-dose tPA improves myocardial (microvascular) reperfusion, as reflected in greater ST-segment resolution, in addition to epicardial flow. This finding may translate into improved clinical outcomes by enhancing myocardial salvage.
- 19 October 1999
- Published by Wolters Kluwer Health in Circulation
- Vol. 100 (16) , 1757-1759
Ebstein’s Anomaly Associated With an Anomalous Coronary Artery, 2 Myocardial Bridges, and a Mahaim Fiber
- 19 October 1999
- Published by Wolters Kluwer Health in Circulation
- Vol. 100 (16) , 1757-1759
Ebstein’s Anomaly Associated With an Anomalous Coronary Artery, 2 Myocardial Bridges, and a Mahaim Fiber